secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000950170-24-089277
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences Q2 revenue $21.4M (-9% YoY); net loss $0.25/sh; FY guidance cut to $81M-$83M
--------------------------------------------------------------------------------

- Total revenue $21.4M (-9% YoY); net loss $12.3M ($0.25/sh) vs $14.8M loss in Q2 2023.
- Surgical Glaucoma revenue $20.2M (-5% YoY); Dry Eye revenue $1.1M (-46% YoY).
- Cash used improved to $9.1M from $12.8M in Q2 2023; cash and equivalents $118.2M.
- Narrowed FY2024 revenue guidance to $81M-$83M (0-2% growth) from prior $81M-$85M; adj. op. expenses $107M-$109M.
- CMS proposes device-intensive status for OMNI procedure, which could increase ASC facility fee 29% in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017024089277/0000950170-24-089277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017024089277/sght-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-089277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer